Verastem Seeks Approval of Duvelisib for Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma
News
Verastem is seeking approval of duvelisib to treat refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the U.S. The new drug application submitted to the U.S. Food and Drug Administration (FDA) also requests the accelerated approval ... Read more